19 February 2021
Visiongain has published a new report on Hereditary Angioedema Treatment Market Report 2021-2031: Forecasts By Drug Class (C1-esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and Others), By Treatment (Prophylaxis, and On-demand), By Route of Administration (Intravenous, Subcutaneous and Oral), By Type (Type I HAE, Type II HAE, Type III HAE), By Drug Type (Generic Drugs, and Branded Drugs), By Patient Demographics (Geriatric Patient, Adult Patient, and Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Hereditary Angioedema Treatment market was valued at US$ xx Million in 2020 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Hereditary Angioedema Treatment market and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.
COVID-19 Impact on Hereditary Angioedema Treatment Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the hereditary angioedema treatment market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:
Increasing Prevalence of Hereditary Angioedema Disorders
The prevalence of hereditary angioedema disorders has increased significantly although it is a rare genetic condition. Hereditary angioedema disorder is a life-threatening disorder and most attacks of hereditary angioedema disorder are difficult to predict which makes it more threatening. Hereditary angioedema disorder is majorly caused by a genetic defect. Hereditary angioedema disorder patients require managing this life-long condition and are prescribed by medication for prevention and treatment of attacks. The increase in the number of cases is increasing the demand of hereditary angioedema treatment for hereditary angioedema disorders treatment. Due to the Increasing prevalence of hereditary angioedema disorders is working as a driver for the hereditary angioedema treatment market.
Increasing focus on Advance Therapeutics
Researchers and manufacturers from across the world are increasing their focus on research and development for advance therapeutics for the treatment of hereditary angioedema disorders and are taking required steps to create or advance therapeutics for hereditary angioedema disorders treatment. Recently, various manufactures have filed new drug applications for C1-esterase Inhibitor, Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor for Type I HAE, Type II HAE, Type III HAE treatment in various counties. Increasing focus on advanced therapeutics and new drug applications will increase the availability of hereditary angioedema treatment therapies in the forecasted period.
Increasing focus on Healthcare Infrastructure
Governments from all over the world are Increasing their focus on healthcare infrastructure and advanced healthcare facilities and are taking necessary steps to create or modify healthcare infrastructure. Healthcare infrastructure in developing nations are undergoing tumultuous changes from the last few years and each change is only for a better healthcare delivery, and to incorporate all the sections of the population. Increasing focus on healthcare infrastructure is expected to increase public spending which is expected to create new opportunities for hereditary angioedema treatment market, Moreover, the public private spending will also aid the market growth during the forecast period. Due to this reason the factor is creating various opportunities for drugs of abuse testing market.
Top companies (Pfizer, Inc., Merck & Co., Inc., and AstraZeneca) constitute more than XX% share of the global Hereditary Angioedema Treatment market. Other companies profiled in the report include: Bristol-Myers Squibb Company, Novartis AG, Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Abbott Laboratories, Boehringer Ingelheim GmbH among) others Some of the key developments are listed below:
● In 2020, Takeda Pharmaceutical Company Limited received European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) approval for a TAKHZYRO (lanadelumab), a pre-filled syringe. TAKHZYRO is especially developed to prevent hereditary angioedema (HAE) in patients aged 12 years and older. The launch will help the company widened revenue generation from a market focused product portfolio.
● In 2017, CSL Behring launched HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]) in the United States. HAEGARDA is administered for prevention of hereditary angioedema (HAE) attacks in adult and adolescent patients. The launch had helped the company to increase its market share in the Hereditary Angioedema Treatment market.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Automation is a rising trend in the supply chain as a way to reduce time to market and enhance efficiency. Automation is appealing for a variety of reasons, the most important of which is that it reduces human contact and hence interference.
02 September 2021
As governments in emerging countries are taking measures to improve healthcare, it is positively impacting the anti-epileptic drugs market growth.
24 August 2021
From a long-term perspective, the rapid growth of the mid-class economy will enhance the demand for OTC products in emerging economies such as China, India and Brazil.
24 August 2021
Growing female population with faecal incontinence to fuel bowel management systems market growth through 2031.